Kirn David 4
4 · 4D Molecular Therapeutics, Inc. · Filed Jan 8, 2024
Insider Transaction Report
Form 4
Kirn David
DirectorChief Executive Officer
Transactions
- Sale
Common Stock
2023-12-15$17.27/sh−28,632$494,432→ 1,230,521 total - Sale
Common Stock
2023-12-18$18.13/sh−4,702$85,243→ 1,225,819 total - Sale
Common Stock
2024-01-04$20.31/sh−40,732$827,202→ 1,185,087 total - Sale
Common Stock
2024-01-05$20.11/sh−133$2,674→ 1,156,850 total - Sale
Common Stock
2024-01-05$19.56/sh−28,104$549,804→ 1,156,983 total
Footnotes (6)
- [F1]Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 17, 2023.
- [F2]The transaction was executed in multiple trades in prices ranging from $17.00 to $17.71, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F3]The transaction was executed in multiple trades in prices ranging from $17.77 to $18.525, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F4]The transaction was executed in multiple trades in prices ranging from $20.02 to $20.545, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F5]The transaction was executed in multiple trades in prices ranging from $19.085 to $20.08, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F6]The transaction was executed in multiple trades in prices ranging from $20.09 to $20.11, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.